April 19 (Reuters) - Bristol-Myers Squibb's cancer
immunotherapy drug, Opdivo, helped advanced head and neck cancer
patients with a dismal prognosis live longer than other standard
treatments, according to data from a late-stage study presented
on Tuesday.
Read more
No comments:
Post a Comment